Research Analysts Issue Forecasts for Century Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:IPSC)

Century Therapeutics, Inc. (NASDAQ:IPSC) – Investment analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Century Therapeutics in a report issued on Thursday, April 11th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Century Therapeutics’ current full-year earnings is ($2.02) per share. William Blair also issued estimates for Century Therapeutics’ Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.46 EPS, Q4 2025 earnings at $0.47 EPS and FY2025 earnings at $1.89 EPS.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.69 million.

A number of other research firms also recently weighed in on IPSC. Piper Sandler reiterated an “overweight” rating and issued a $9.00 price target (down from $10.00) on shares of Century Therapeutics in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Century Therapeutics in a report on Friday, March 15th. Finally, Canaccord Genuity Group lifted their price objective on shares of Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, March 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Century Therapeutics Trading Down 6.1 %

Shares of IPSC opened at $3.67 on Monday. Century Therapeutics has a 12 month low of $1.28 and a 12 month high of $5.51. The firm’s 50 day moving average is $4.31 and its 200-day moving average is $3.08. The stock has a market capitalization of $237.89 million, a PE ratio of -1.60 and a beta of 1.33.

Insider Activity at Century Therapeutics

In related news, insider Adrienne Farid sold 22,831 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $5.14, for a total value of $117,351.34. Following the completion of the transaction, the insider now owns 114,149 shares of the company’s stock, valued at approximately $586,725.86. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 25,509 shares of company stock valued at $127,635. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Century Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Century Therapeutics by 31.5% during the first quarter. Bank of New York Mellon Corp now owns 43,881 shares of the company’s stock worth $552,000 after purchasing an additional 10,524 shares during the last quarter. MetLife Investment Management LLC bought a new stake in Century Therapeutics during the 1st quarter worth approximately $153,000. Rhumbline Advisers acquired a new position in Century Therapeutics in the 1st quarter valued at approximately $188,000. BlackRock Inc. raised its stake in shares of Century Therapeutics by 24.3% during the first quarter. BlackRock Inc. now owns 1,028,257 shares of the company’s stock valued at $12,946,000 after acquiring an additional 200,834 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Century Therapeutics by 49.6% during the first quarter. Vanguard Group Inc. now owns 819,762 shares of the company’s stock valued at $10,320,000 after acquiring an additional 271,760 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.